ストックスクリーナーアプリを入手
295.02
1.23%
-3.68
アフターアワーズ：
295.02
前日終値:
$298.70
開ける：
$295.71
24時間の取引高:
374.47K
Relative Volume:
0.77
時価総額：
$13.57B
収益：
$2.76B
当期純損益:
$1.11B
株価収益率:
12.96
EPS:
22.77
ネットキャッシュフロー:
$898.10M
1週間 パフォーマンス:
-1.91%
1か月 パフォーマンス:
+0.88%
6か月 パフォーマンス:
-25.78%
1年 パフォーマンス:
+13.25%
1日の値動き範囲:
$290.02
$298.48
1週間の範囲:
$290.02
$319.40
52週間の値動き範囲:
$260.41
$417.81
United Therapeutics Corp Stock (UTHR) Company Profile
名前
United Therapeutics Corp
セクター
電話
(301) 608-9292
住所
1000 SPRING ST, SILVER SPRING, MD
UTHR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
295.02 | 13.57B | 2.76B | 1.11B | 898.10M | 22.77 |
|
ZTS
Zoetis Inc
|
149.87 | 69.33B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.17 | 48.09B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.67 | 46.34B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.12 | 18.47B | 16.54B | -1.64B | 749.00M | -1.45 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-07-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | アップグレード | Goldman | Sell → Neutral |
| 2024-02-05 | 開始されました | Leerink Partners | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2022-12-06 | 開始されました | UBS | Buy |
| 2022-12-05 | 開始されました | Goldman | Sell |
| 2022-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2022-09-20 | 繰り返されました | BofA Securities | Underperform |
| 2022-09-19 | 再開されました | Wedbush | Outperform |
| 2022-02-11 | 開始されました | BTIG Research | Neutral |
| 2021-07-14 | アップグレード | Argus | Hold → Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-02-01 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-06-25 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-03-10 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-27 | アップグレード | Cowen | Market Perform → Outperform |
| 2020-01-31 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 開始されました | BofA/Merrill | Underperform |
| 2019-08-01 | アップグレード | Jefferies | Underperform → Hold |
| 2019-08-01 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | アップグレード | UBS | Sell → Neutral |
| 2019-05-09 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | アップグレード | Standpoint Research | Hold → Buy |
| 2018-08-08 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 繰り返されました | Barclays | Underweight |
| 2018-01-18 | 再開されました | Credit Suisse | Underperform |
| 2017-12-27 | 繰り返されました | Wedbush | Outperform |
| 2017-04-27 | 繰り返されました | Wedbush | Outperform |
| 2017-03-30 | 開始されました | UBS | Sell |
| 2017-03-16 | 開始されました | Credit Suisse | Underperform |
すべてを表示
United Therapeutics Corp (UTHR) 最新ニュース
United Therapeutics (UTHR) Target Price Lowered by Argus, Retains Buy Rating | UTHR Stock News - GuruFocus
United Therapeutics (UTHR) Receives Reiterated "Buy" Rating from HC Wainwright | UTHR Stock News - GuruFocus
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia - GlobeNewswire Inc.
United Therapeutics (UTHR) Gets a Hold from Wells Fargo - The Globe and Mail
BofA raises United Therapeutics stock target to $321 - Investing.com Australia
United Therapeutics (UTHR): Morgan Stanley Raises Price Target | - GuruFocus
BofA raises United Therapeutics stock target to $321 By Investing.com - Investing.com Canada
United Therapeutics (UTHR) Analyst Update: JP Morgan Maintains R - GuruFocus
United Therapeutics (UTHR) Analyst Update: JP Morgan Maintains Rating | UTHR Stock News - GuruFocus
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insig - GuruFocus
United Therapeutics Corporation (NASDAQ:UTHR) Q1 2025 Earnings Call Transcript - Insider Monkey
Avepoint, Meta, United Therapeutics - TradingView
United Therapeutics: Q1 Earnings Snapshot - New Haven Register
United Therapeutics Corp (UTHR) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
United Therapeutics Reports Strong Q1 2025 Growth - TipRanks
United Therapeutics Corp. Reports Record Revenue Growth - TipRanks
Earnings call transcript: United Therapeutics Q1 2025 beats expectations - Investing.com
United Therapeutics Corp Surpasses Q1 2025 Estimates with $7.18 EPS and $794.4 Million Revenue - GuruFocus
United Therapeutics (UTHR) Surpasses Q1 Earnings Expectations - GuruFocus
United Therapeutics beats Q1 estimates, shares edge higher - Investing.com
United Therapeutics Q1 Earnings, Revenue Rise - marketscreener.com
United Therapeutics Q1 2025 slides: revenue jumps 17%, organ transplant milestone nears - Investing.com
UNITED THERAPEUTICS Corp SEC 10-Q Report - TradingView
United Therapeutics Sells Priority Review Voucher to AbbVie - CHEManager
United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect - The Globe and Mail
United Therapeutics secures $2.5 billion credit facility - Investing.com
United Therapeutics Enters Credit Agreement With Wells FargoSEC Filing - marketscreener.com
United Therapeutics secures $2.5 billion credit facility By Investing.com - Investing.com UK
United Therapeutics Corporation Announces Credit Agreement Established for A $2.5 Billion Revolving Facility - marketscreener.com
Wells Fargo cuts United Therapeutics stock rating to Equal Weight By Investing.com - Investing.com South Africa
Wells Fargo cuts United Therapeutics stock rating to Equal Weight - Investing.com Australia
This United Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - Benzinga
Demystifying United Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Liquidia Corp files patent infringement suit against United Therapeutics By Investing.com - Investing.com Canada
Liquidia Corp files patent infringement suit against United Therapeutics - Investing.com
BofA Securities Upgrades United Therapeutics to Neutral From Underperform - marketscreener.com
United Therapeutics stock rating lifts to neutral at BofA - Investing.com
United Therapeutics stock rating lifts to neutral at BofA By Investing.com - Investing.com UK
United Therapeutics (UTHR) Stock Upgrade Amid Valuation Drop | U - GuruFocus
United Therapeutics (UTHR) Stock Upgrade Amid Valuation Drop | UTHR Stock News - GuruFocus
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference | UTHR Stock News - GuruFocus
Major Phase 3 Trial Results: United Therapeutics Reveals New Lung Disease Treatment Data at ATS 2025 - Stock Titan
United Therapeutics director Raymond Dwek sells $855,480 in stock - Investing.com Australia
United Therapeutics Schedules Key Q1 2025 Financial Results: What Pharma Investors Should Watch - Stock Titan
United Therapeutics director Raymond Dwek sells $855,480 in stock By Investing.com - Investing.com India
United Therapeutics Corp (UTHR) 財務データ
収益
当期純利益
現金流量
EPS
United Therapeutics Corp (UTHR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MAHON PAUL A | EVP & GENERAL COUNSEL |
May 01 '25 |
Sale |
300.93 |
11,000 |
3,310,201 |
36,781 |
8.36%
1.28%
大文字化:
|
ボリューム (24 時間):